Hereditary hemochromatosis
Hereditary hemochromatosis (HH) is a genetic disease characterized by an excessive (unregulated) entry of iron into the bloodstream with increased iron deposition in the parenchymal cells of a variety of organs leading to their failure [1, 2] . Mutations of a number of genes involved in the hepcidin-ferroportin axis, have been identified as being responsible for this disease [3] . A defect in the hemochromatosis gene (HFE) is the most common form of HH, also known as the classic form or type 1 (type 1 HH), where the principal mutation is represented by a substitution of tyrosine for cysteine at position 282 of the HFE gene (C282Y). Although the homozygosity for the C282Y mutation is the most common genotype of HH type 1 for clinical iron overload, a compound heterozygote mutation for HFE: the C282Y and the common alteration characterized by the substitution of aspartate for histidine at aminoacid 63 (H63D) or other rare HFE mutations (S65C, G93R, I105T, etc.) may results as well in a milder clinical evident iron overload. Another three rare additional HH forms, non-HFE-related, have been identified including juvenile haemochromatosis (type 2 HH), which can be caused by a Abstract Hereditary hemochromatosis (HH) is a genetic disorder of iron overload and subsequent organ damage. Five types of HH are known, classified by age of onset, genetic cause, clinical manifestations and mode of inheritance. Except for the rare form of juvenile haemochromatosis, symptoms do not usually appear until after decades of progressive iron loading and may be triggered by environmental and lifestyle factors. Despite the last decades discovery of genetic and phenotype diversity of HH, early studies showed a frequent involvement of the endocrine glands where diabetes and hypogonadism are the most common encountered endocrinopathies. The pathogenesis of diabetes is still relatively unclear, but the main mechanisms include the loss of insulin secretory capacity and insulin resistance secondary to liver damage. The presence of obesity and/or genetic predisposition may represent addictive risk factor for the development of this metabolic disease. Although old cases of primary gonad involvement are described, hypogonadism is mainly secondary to selective deposition of iron on the gonadotropin-producing cells of the pituitary gland, leading to hormonal impaired secretion. Cases of hypopituitarism or selected tropin defects, and abnormalities of adrenal, thyroid and parathyroid glands, even if rare, are reported. The prevalence of individual gland dysfunction varies enormously within studies for several bias due to small numbers of and selected cases analyzed, mixed genotypes and missing data on medical history. Moreover, in the last few years early screening 1 3 mutation in the hemojuvelin (HJV) gene (type 2A HH), or by mutation in the hepcidin antimicrobial peptide (HAMP) gene (type 2B HH); the HH type 3, caused by mutation in the transferrin receptor-2 (TFR2) gene and, finally, the HH type 4, caused by mutation in the ferroportin (SLC40A1) gene that include two sub-forms: A with loss and B with gain of protein function, respectively. All forms of HH have an autosomal recessive inheritance, except for type 4 HH that has an autosomal dominant inheritance [1] [2] [3] (Table 1) .
Despite the type 2 HH, symptoms do not usually appear until after decades of progressive iron loading. However, depending on the gene involved, the iron influx into the plasma and its organs damage differ according to the phenotype. The HH type 1 and type 4 have a milder late-onset phenotype where symptoms usually appear in the third to fifth decades of life, whereas in HH type 2 iron rapidly accumulates early in life, and symptoms usually start during childhood. HH type 3 is an intermediate phenotypes between the typical adult-onset of the HH type 1 ad the two juvenile type 2 forms, where symptoms generally begin before age 30 [1, 2] .
Although acquired factors for increased iron absorption, such as excessive alcohol intake and chronic hepatitis C or B infections, may favor the development of hepatic damage, none of them per se is able to induce iron overload in the range observed in HH, suggesting a minor role of acquired risk factor in the natural history of the disease [4] . However, it cannot be ruled out that HCV and/or alcohol enhance the underlying defect of iron metabolism leading to phenotypically expressed hemochromatosis [5] .
The homozygous mutation accounting for the C282T substitution of the HFE gene is the most frequently inherited form with a fairly high prevalence in subjects of Northern European origin [1] . The other forms are very much rare and have been reported in different ethnic groups, except for the type 3 HH that has mainly been described in Italian families [6] .
According to the genetic forms, the clinical manifestation usually ranges from simple biochemical abnormalities to severe organ damage and disease such as liver cirrhosis, arthritis, diabetes mellitus, cardiomyopathy and hypogonadism. In the type 2 HH, where the altered gene plays a dominant role in the hepcidin synthesis, iron rapidly accumulates at a younger age reaching high levels with full-blown organ disease. Hypogonadism or cardiopathy in type 2 HH can be the initial symptoms that may appear before the onset of liver damage [2, 7] . Instead, if the gene mutated is less critical, such as the classical HFE, mutation, a gradual iron loading will occur leading to a milder phenotype with later onset of symptoms. Moreover, intermediate phenotypes such as the type 4 HH have also been described in which iron accumulates predominantly in the hepatic macrophages reticuloendothelial (Kupffer cell) rather than parenchymal hepatic cells [2] . In type 4 HH, therefore, subjects are mostly asymptomatic and only cases of iron overload involving parenchymal cells may present with symptoms typical of the type 1 HH.
Early screening and awareness of the disease among physicians have allowed a prompt diagnosis in most cases at early stages in otherwise asymptomatic patients [2, 3] .
For a detailed overview of both pathogenesis and diagnosis of HH, the reader can refer to a recent review by Pietrangelo [2] .
This review focuses on the description and examination of the literature on all the main endocrinopathies associated with HH, including diabetes, hypogonadism and less frequent disorders of pituitary, adrenal, thyroid and parathyroid gland function. To examine all the HH endocrinopathies, we reported data obtained by recent and old studies, the latter referring to the era prior to the genetic discovery defined as idiopathic hemochromatosis.
Endocrine dysfunction related to HH Diabetes
In early studies, the prevalence of diabetes, among patients with HH, was originally estimated to be fairly high, between 40 and 63 % [8] . After the discovery of the genetic mutations and therefore earlier diagnosis and treatment the prevalence dropped to approximately 13-23 %, where the most common form analyzed was HH type 1 [9] [10] [11] . In the other genetic forms of HH, the prevalence of glucose abnormalities has not been well defined. A higher prevalence of impaired glucose tolerance (IGT) in patients with a juvenile disease (HH type 2) (58 %) in comparison with C282Y homozygous HH type 1 (27 %) and with HH type 3 subjects (9.1 %) has been shown [7] . Regarding the type 4 HH, diabetes has been shown in up to 25 % of patients [12] .
To date several large epidemiological studies have examined the prevalence of diabetes in HH and, vice versa, the frequency of HFE genotype mutations in patients with [13, 14] .
A well-performed cross-sectional study conducted in a selected HH population (all with homozygous mutations for HFE and with no pre-existing metabolic disease) estimated the prevalence of diabetes and glucose abnormalities with an oral glucose tolerance test (OGTT) and intra-venous glucose tolerance test (IVGTT) [15] . The authors found a higher prevalence of diabetes (23 %) and IGT (30 %) in HH type 1 subjects compared with age-and weight-matched controls, which suggests that a significant frequency of abnormal glucose metabolism in individuals with HFE homozygous mutations developed prior to the onset of full-blown diabetes.
Although numerous questions regarding the pathogenesis of diabetes in HH remain unanswered, it is well accepted that the main mechanisms involved are: (1) β-cell damage with insulin deficiency; and (2) insulin resistance due to hepatic damage. However, the presence of obesity and/or a genetic predisposition may trigger the development of this metabolic disease (Fig. 1) .
Undoubtedly, β-cell damage with insulin deficiency is the main mechanism involved in the development of diabetes in patients with HH. In fact, as shown in mouse model with deletion of the HFE −/− gene [16] and in HH type 1 patients [15] , iron excess causes β-cell oxidant stress with apoptosis of pancreatic islets and desensitization of glucose-induced insulin secretion with reduced insulin secretory capacity. Interestingly, this trend toward a decreased insulin secretory capacity has also been associated with a compensatory increase in insulin sensitivity in HH animals [17] and humans [15] . In a human study, HH type 1 patients with IGT had a decrease in acute insulin response glucose and a trend toward increased insulin sensitivity at IVGTT, with no evidence for insulin resistance compared to normal glucose tolerant controls [15] . On the other end, HH type 1 patients with diabetes were characterized by decline in acute insulin response to glucose and insulin resistance. These data suggest that insulin resistance is not the primary event leading to haemochromatosis-related diabetes, rather it seems to develop lately in the transition form IGT to diabetes. In these patients, insulin resistance appears to be the result of obesity and/or hepatic iron damage. In fact, as shown by Hramiak et al. [18] , in the absence of cirrhosis and diabetes, insulin sensitivity was normal in haemochromatosis patients.
A possible explanation for this trend toward increased insulin sensitivity observed in type 1 HH patients prior to the onset of diabetes seems to be related to adiponectin, an adipokine secreted by adipocytes with insulin sensitizing action. It has been shown that adipocytes express not only common regulators of iron homeostasis, such as ferritin and iron regulatory proteins but also iron-related proteins with restricted tissue expression, including transferrin receptor 2, HFE, hepcidin and ferroportin [19] . Moreover, in a 
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Obesity + GeneƟc predisposiƟon mouse model and in culture adipocytes, it has been shown that iron negatively regulates adiponectin transcription via FOXO1-mediated repression, which suggests a role for adipocytes in modulating metabolism through adiponectin in response to iron stores [19] .
Therefore, the regulation of adiponectin by iron seem to elucidate the glucose homeostasis in HH. In both animals and humans, HH is associated with high levels of adiponectin, while subjects with metabolic syndrome and high ferritin levels present with low adiponectin concentrations [15, 19] .
A different deposition of iron has been shown between HH and subjects with metabolic syndrome and high ferritin levels. Despite a systemic iron overload, a decreased hepcidin synthesis and increased ferroportin expression with low iron accumulation in adipocytes, macrophages and gut enterocytes have been observed in type 1 HH. The lack of iron deposition in these cells may explain an increased adiponectin secretion with improved glucose tolerance and increased insulin sensitivity in these subjects. On the contrary, in subjects with metabolic syndrome and high ferritin levels, hepicidin level is elevated and causes a downregulation of ferroportin expression with iron accumulation in adipocytes with a reduction in adiponectin levels and insulin resistance [15, 19] .
Obesity and/or cirrhosis are well-known causes of insulin resistance that might further trigger the development of diabetes in haemochromatosis patients because of their inability to compensate for the increased insulin demand as a result of β cell dysfunction. Moreover, in a study conducted in 159 HFE C282Y homozygous patients, body mass index and diabetes reported in family members, in particular maternal diabetes, were found to predict the risk for developing diabetes, among several variables, including age, sex, ethanol intake, iron overload, and cirrhosis [20] .
Although HH is most commonly associated with type 2 diabetes, rare cases of late-onset type 1 diabetes have also been reported For example, in an unselected Danish population, more subjects with homozygous for C282Y among a population with type 1 diabetes were reported in comparison with those found in a general control population (1.26 % type 1 HH vs 0.25 % controls) [21] .
Phlebotomy, the gold standard treatment in any form of HH, has a variable impact on diabetes control. In general, in HH patients who do not yet have complications/ organ damage, an improvement of insulin secretory capacity and normalization of glucose tolerance [18, 22] has been reported, by contrast no significant improvement in HH patients already complicated by cirrhosis or diabetes has been described. A good example is represented by the study of Hatunic et al. [22] who evaluated eleven newly diagnosed subjects with type 1 HH with abnormal glucose tolerance (seven with IGT and five with diabetes) at baseline and after normalization of ferritin and transferrin saturations by phlebotomy for 12 months. Four of seven IGT patients improved their glucose tolerance status, two progressed to diabetes whereas one IGT and five diabetes patients did not change. Therefore, normalization of ferritin and transferrin saturation by phlebotomy in subjects with HH may lead in selected patients to an improvement of glucose intolerance. In a large old study exploring the effect of phlebotomy on diabetes control, 16 of 56 patients (28 %) on insulin or oral agents showed improved glucose control following phlebotomy therapy. Eleven of these patients decreased their insulin requirements, two were able to stop insulin therapy and required no further treatment, three switched from insulin to oral hypoglycemic agents and carbohydrate restriction, whereas in seven patients (12 %) the glycemic control worsened [23] . Phlebotomy may, therefore, prevent the progression of the disease if started immediately, although the majority of diabetic patients will experience no significant change or worsening in their glucose metabolism control.
Hypogonadism
The most common non diabetic-endocrinopathy in HH patients is hypogonadism. The original defect seems to be located mainly at pituitary level where iron deposits mostly in the gonadotrope cells leading to impaired cell function and abnormal hormonal secretion [24] . Early studies conducted in male selected patients, defined as idiopathic hemochromatosis before the advent of genetic tests and with advanced disease, reported a wide prevalence of hypogonadism ranging from 10 to 100 % [25] [26] [27] [28] [29] [30] [31] [32] , the majority presenting with clinical features of androgen deficiency associated with gonadotropin dysfunction. A recent Irish study performed in post-genetic era and conducted in a large cohort of unselected patients with type 1 HH showed that hypogonadism was a relatively uncommon complication [33] . The study found that only 9 out of 141 type 1 HH male (6.4 %), diagnosed in a single center over 20 years, had abnormally low sex hormone levels with inappropriately low gonadotropin concentrations. By comparing the hypogonadic with eugonadic HH type 1 patients, they also showed that, at first diagnosis, the former group had a higher prevalence of hepatic siderosis on liver biopsy, hepatic cirrhosis and ferritin levels greater than 1500 ng/ml and a tendency to a higher proportion of diabetes suggesting that in patients with type 1 HH, the hypogonadic state can be considered a sign of advanced disease. (The majority of these studies are summarized in Table 2 ). Differently, HH type 2 patients may present with an early manifestation of clinical and biochemical evidence of hypogonadotropic hypogonadism, occurring sometimes years before the onset of cardiac or hepatic manifestation [2] . In 2002 De Gobbi et al. [7] published the largest records of HH type 2 patients (n = 26) and compared the clinical expression of these subjects with that of type 1 (n = 93) and 3 (n = 11) HH counterparts. The authors found that patients with type 2 HH were statistically younger and presented with a more severe iron burden than type 1 and 3 HH subjects where the commonest symptom of presentation was hypogonadotropic hypogonadism. Almost all these patients were hypogonadic at the end of the second decade (96 %) in comparison with those reported in the type 1 (18.4 %) and 3 HH (27.3 %) subjects. Instead, the occurrence of hypogonadism in patients with type 4 HH, is just mentioned without any available prevalence [2, 3] .
Clinically, the most common symptoms in men are reduced body hair, loss of libido and impotence, associated or not with altered fat distribution, rarely gynecomastia and testicular atrophy of variable degree.
Subnormal testosterone levels with low or inappropriately normal basal gonadotropin concentrations and a blunted or no response of FSH and LH to LHRH administration are the main hormonal characteristics reported in male hypogonadic HH patients, thus supporting a pituitary dysfunction [25-30, 32, 33] .
However, in old studies few cases with hypothalamic [31] or a gonadal dysfunction alone [34] or in association with pituitary defect have been reported [25, 35, 36] . Piperno et al. [31] found lower basal mean serum testosterone and gonadotropin levels, with a normal testosterone response to human chorionic gonadotropin (hCG) and a normal increment of LH after LHRH stimulation in seven untreated men with idiopathic HH and relatively low iron store and no hepatic injury without clinical evidence of hypogonadism, compared with matched control subjects, thus suggesting a potential combination of initial hypothalamic defect, at an early stage of iron overload, with subsequent involvement of pituitary and gonad as iron overload increase. By contrast, this hypothesis was not confirmed by other study [32] that showed no increase in testosterone and LH levels in selected patients with idiopathic HH and hypogonadism before and after chronic pulsatile LHRH therapy over 15-30 days, strengthening the presence of a pituitary lesion rather than a hypothalamic defect.
In addition exceptional old cases of idiopathic HH patients with advanced disease and primary hypogonadism have also been described [34] , the majority of them associated with pituitary defects and characterized by an absent or blunted testosterone response to hCG stimulation with a concomitant impaired LH response to LHRH administration [25, 35] .
In summary, even if an involvement of the hypothalamus at an early stage of the disease can not be completely excluded, the predominance of HH studies do support a primary pituitary defect with a potential gonadal damage in case of advanced and uncontrolled disease. Notably, in the majority of patients affected by HH, the testes are normal and in some cases atrophic due to the insufficient gonadotropin secretion secondary to iron pituitary accumulation [37] .
Studies in HH females have insufficient patient number to evaluate the prevalence of hypogonadism and the exact related endocrine nature. However, the occasional cases reported are characterized by hypogonadotropic hypogonadism [38] [39] [40] [41] . Women in the reproductive age may usually present with secondary amenorrhea, abnormal menses and ovulation, infertility, premature menopause and loss of libido, whereas in post-menopausal women loss of libido is the only symptom. Kelly et al. [34] studied 23 women with idiopathic haemochromatosis without any clinical or biochemical evidence of hypogonadism, whereas Mc Dermott et al. [33] found only two out of the thirty-eight type 1 HH female patients with low gonadal hormonal levels and inappropriately low gonadotropin concentrations. On the contrary, in type 2 HH, hypogonadotropic hypogonadism represent also in female one the main clinical manifestation of the disease due to the rapid and most severe form of iron overload [7] . Although HH in females has received little attention, generally the prevalence of hypogonadism appears to be distinctly lower than that in men with the same disorder, possibly because of lower iron accumulation due to iron loses through menstruation, childbearing and lactation.
The appropriate treatment of HH patients with hypogonadism is testosterone replacement in males and cyclical estrogen and progesterone therapy in fertile females. Interestingly, it has been shown that gonadotropin cell dysfunction induced by the excessive iron overload can be reversed when specific treatment is introduced early in the progression of the disease [34] . In particular, there are several reports on successful phlebotomy therapy in hypogonadic patients with HH able to totally or partially recover both pituitary and gonadal function [40, [42] [43] [44] .
Therefore, hormonal substitution treatment should be withdrawn when body iron stores have been normalized to reassess the gonadotropin secretion being aware that the recovery of pituitary function may take several months.
Hypopituitarism and other pituitary tropin defects
Although iron deposition has been indistinctly described in pituitary gonadotroph, somatotroph, lactotroph, corticotroph and thyrotroph cells, accumulation of iron appears to be more pronounced in gonadotrophs than in other cell types, with somatotrophs and lactotrophs containing similar amounts of iron as may corticotrophs and thyrotrophs [24] . In general, panhypopituitarism is relatively rare in these patients. In fact the secretion of ACTH and TSH is usually well preserved [34] , although single old case reports have been described with other pituitary hormone deficiencies [25, 27, 43, 45, 46] . Notably, a recovery of the pituitarythyroidal and adrenal axis following iron depletion with therapeutic phlebotomy and interruption of specific hormonal replacement therapy has also been reported [43, 45] .
A dysfunction of the lactotroph [31, 46] or somatotroph [25, 27, 46, 47] cell secretory capacity has been shown by functional tests in few studies conducted in HH patients prior to the genetic discovery showing conflicting results. In particular, a decreased PRL response to TRH stimulation [31, 46] and an abnormal GH response to insulin-induced hypoglycemia [27] or a blunted GH response to GHRH stimulation [25, 46, 47] have been reported by some researchers but not subsequently confirmed by others [26, 29] leaving these issues inconclusive (see Table 2 ).
Part of these discrepancies, in particular regarding the GH secretion might be explained by several biases: (1) in most cases the coexistence of an hypogonadic condition (which is known to induce a subnormal GH increase after appropriate stimuli); (2) the difficulty to achieve adequate hypoglycemia (able to stimulate the release of GH itself) at the insulin hypoglycemic test [25, 46] . Furthermore, the heterogeneity of the functional tests used to show the tropin defect may represent another confounding variable.
In summary, a panhypopituitarism as well as a single tropin defect beside hypogonadotropic hypogonadism is relatively uncommon. Undoubtedly, further accurate research with specific functional tests in well-defined HH patients may be required to definitely investigate these potential hormonal defects.
Thyroid dysfunction
It is well known from autoptic studies that in HH patients iron tends to deposit not only in the anterior pituitary gland but also in the thyroid gland [24, 48] . However, cases of thyroid dysfunction in such patients occur rarely and are usually detected in subjects who already have hepatic cirrhosis and/or other endocrine disorders at an end-stage disease [49] . This may be explained by the fact that iron usually deposits in a minority of thyrotroph cells and to a mild degree with respect to the gonadotroph cells [28] Although abnormalities of the pituitary thyrotroph cells function in patients with HH are well described [25, 43, 45] , primary thyroid dysfunction leading to either hypothyroidism or hyperthyroidism in patients with HH has also been reported [50] ; particularly in men with HH type I [49] . A possible link between type 1 HH and autoimmune thyroid disease has been suggested, based on the exposure of cellular antigens, like thyroid peroxidase (TPO) and thyreoglobulin (Tg), due to iron deposition and damage of the thyroid cell, allowing a subsequent production of anti-thyroid antibody [49] [50] [51] . However, recent larger studies did not confirm this hypothesis since no significant differences in prevalence of thyroid disease between HH type 1 patients and non affected controls have been shown [52, 53] . In a cohort of 150 Irish patients with HH type I, only one case of male primary hypothyroidism (0.6 %), two cases of female subclinical hypothyroidism (1.3 %) and no cases of hyperthyroidism have been described [53] . Similarly in the Hemocromatosis and Iron Overload Screening Study (HEIRS), where serum TSH and free T4 levels were measured in 176 white HFE C282Y homozygote patients and 312 controls, the prevalence of hypothyroidism or hyperthyroidism was very low and did not differ between the two groups (1.7 % in HH and 1.3 % in controls; 0 % in HH and 1.0 % in controls, respectively) [52] . Moreover, even if the transferrin saturation was significantly higher in type 1 HH group with respect to controls, this study did not find any association between the severity of iron overload and primary thyroid dysfunction. Accordingly, it has been reported that patients with primary hypothyroidism and heavy iron overload resulting from transfusion do not have positive titres of antibodies [53] . Anecdotally, an autoimmune thyroiditis has also been described in two siblings with type 2 HH, however, without any evidence of a pathogenetic link [54] . Therefore, these studies support the concept that a primary thyroid dysfunction may occasionally occur in all forms of HH and that this association is likely coincidental.
Adrenal dysfunction
In the adrenal glands, iron may somehow deposit predominantly in the aldosterone secreting zona glomerulosa, with respect to the inner zona fascicolata and reticolaris [24] . Surprisingly, most of the studies performed so far evaluated the pituitary adrenal axis but very few investigated the mineral corticoid status. Old studies performed in idiopathic HH patients showed a relatively high prevalence of glucocorticoid deficiency due to pituitary dysfunction and primary adrenal failure [27] . However, similar findings have not been confirmed by subsequent detailed studies that failed to demonstrate any abnormality of the pituitaryadrenocortical axis in HH patients using validated diagnostic criteria either with the 1-24 ACTH (Synacthen) test [25] or the insulin stress test [26, 47, 55] . Varkonyi et al. [56] described only one case of a young type 2 HH male, aged 25, with cardiomyopathy and isolated adrenal insufficiency with no evidence of hypogonadic hypogonadism, who in the previous 6 months had developed frequent nausea, weight loss, brownish skin and postural hypotension. In this patient, glucocorticoid and mineralocorticoid replacement therapy in association with regular phlebotomy led to a completely recovery from symptoms.
As mentioned above, there are few exceptional old case reports describing abnormal mineralocorticoid secretion with normal glucocorticoid release in patients with idiopathic HH, [57, 58] . However, in a study by Walsh et al. [55] both the glucocorticoid and the mineralocorticoid status was, respectively, assessed in fifteen and eleven idiopathic HH patients by means of the short 1-24 ACTH test, the overnight metyrapone test, the insulin stress test, and the plasma aldosterone and renin activity in basal and in the upright position. In all cases no abnormalities were detected, supporting the concept that in patients with HH an adrenocortical dysfunction is likely rare.
In conclusion, glucocorticoid function appears to be normally preserved in almost all HH patients and this could be explained by the pattern of iron distribution within the adrenal gland, specifically by a mild iron deposition in the zona fasciculata. In addition, although severe iron accumulation has been described in the adrenal zona glomerulosa cells, defects of mineralocorticoid secretion have been rarely reported.
Parathyroid defects and osteoporosis
Metabolic osteopathy is a frequent manifestation of HH, but its pathogenesis is still unclear. Although parathyroid disorders have been suggested as potential causative factors, parathyroid defects are very rare in patients with HH, even if iron deposition on parathyroid glands has been described [47] . Nonetheless, a hypoparathyroid state and evidence of osteoporosis have been reported in sporadic cases of HH, usually associated with multiple gland defects [47] , Pawlotsky et al. [59] studied 27 patients with idiopathic HH and found elevated serum PTH levels in seven patients, but only one presented with elevated calcium concentrations, whereas the remainder had normal calcium levels but an increased bone resorption surface, indirectly supporting a primary parathyroid defect. At variance, further studies found normal concentrations of serum calcium, phosphorus and PTH in type 1 HH patients with or without associated hypogonadism and osteoporosis [60, 61] . The presence of an increased concentration of a PTH midfragment containing the 44-68 region, that unlike the intact PTH 1-84 has no hypercalcemic activity, has been reported in several cases of HH [62] . In a large cohort of patients with HH (127 men and 51 women, partly with a genetic diagnosis of C282Y homozygosity and the remaining with histological and clinical criteria of HH) serum PTH 44-68 levels proved to be elevated in nearly one third of them (ten fold higher than the intact hormone), while serum intact PTH 1-84 levels were elevated in only seven patients, all presenting with normal total or ionized calcium values [62] . A direct production and secretion by the parathyroid glands or an increase in hepatic metabolism of intact PTH have been suggested as sources of this PTH fragment [62] . However, the elevated serum PTH 44-68 levels, regardless of the origin (parathyroid glands or liver) correlated positively with ferritin levels, suggesting a connection between iron overload and the PTH midfragment production. Moreover, PTH 44-68 levels correlated positively with the number of joints with chondrocalcinosis or subchondral arthropathies suggesting a role in the osteoarticular changes of HH patients [62] .
Several studies have reported a significant bone loss in patients with idiopathic HH with a prevalence of osteoporosis of approximately 25-34 % and of osteopenia of 40-79 % [60, 63, 64] . The bone disorder has been correlated with the severity of iron overload, regardless of the presence of hypogonadism, cirrhosis and 25-hydroxyvitamin D deficiency, all factors that may worsen bone architecture [60, 63, 64] . In these cases, decreased bone mineral density (BMD) seems to be more pronounced at femoral neck rather than at the lumbar spine, which support a more severe involvement of cortical than trabecular bone [42, 45, 64] .
Inadequate bone formation, excessive bone resorption or both are usually the causes of the development of osteoporosis in patients with HH, the pathophysiological aspects of which are still unclear. On the other hand, in vivo and in vitro studies have demonstrated a direct toxicity of excessive iron on BMD, by inhibiting osteoblastic cell proliferation and activity with bone apposition [60, 65] without directly altering reabsorption, which, however, is increased in the presence of a hypogonadic state. Moreover, excessive iron has been shown to inhibit bone crystal growth, with significant changes in crystallinity and carbonate substitution [66] . Interestingly, deprivation of sex steroids is characterized by an increased osteoclastic bone resorption particularly in type 2 HH patients, who may have an early involvement of pituitary dysfunction [67] . On the other hand, elevated bone resorption and decreased bone formation parameters on bone biopsy have been described in hypogonadic males with HH with osteoporosis compared to their eugonadic counterpart [68] . Notably, no difference between a specific genetic background and the prevalence of osteoporosis has been reported [64] , which suggests a direct responsibility of iron overload. However, patients with type 2 HH who are characterized by severe iron excess and early multi-glandular defects are nearly always affected by osteoporosis [64, 65] . Severe osteoporosis may obviously increase the risk of vertebral fractures [60] , and spontaneous vertebral fractures can be the presenting clinical features of patients with HH [69] .
Notably, bone mineral density has been reported to ameliorate after normalization of ferritin levels achieved by frequent phlebotomies [64, 67, 70] .
Conclusions
The majority of the studies on the endocrine function in patients with HH are too small and often include selected cases, while important data on medical history, particularly on alcohol intake and iron status at the time of the investigation, are often missing. Moreover, most of the available literature is relatively old and no longer representative of the current experience where the diagnosis is made at an earlier stage of the disease when the patients are mostly asymptomatic and usually with a defined genetic status. Diabetes or impaired glucose tolerance states represent the most frequent complications. Among the non-diabeticendocrinopathies encountered in HH patients, hypogonadism seems to be the most relevant, at least in males, predominantly due to a pituitary damage. Hypogonadotrophic hypogonadism is often isolated, although association with other pituitary deficiencies, particularly of PRL and GH secretion has been rarely reported. Moreover, deficiencies of pituitary TSH and ACTH are exceptional as well as those involving a primary dysfunction of gonads, adrenals, thyroid and parathyroid. By contrast, osteopenia and osteoporosis are relatively common in patients with HH, due to a direct iron effect on bone resorption and to the frequent coexistence of androgen deficiency. Removal of excess iron by therapeutic phlebotomy reduces the severity and duration of iron deposition thereby decreasing morbidities. Metabolic abnormalities can be ameliorated and hormonal dysfunctions can be reversed if treatment is started during the early phases of the disease, particularly before the development of cirrhosis.
In conclusion, an assessment of pituitary gonadal function, glucose and bone metabolism is recommended in all types of HH patients at first diagnosis, whereas the reaming detection of other hormonal defect are suggested only in symptomatic patients (see Table 3 ). The early intervention in HH patients may in turn favor a normal life expectancy. However, much larger studies on endocrine and metabolic disorders in patients with HH are warranted, particularly in the early phase of the disease. In addition, a multidisciplinary approach starting with a validated diagnostic protocol and early therapeutic intervention, and continuing with a long-term structured follow-up are also desirable.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent For this type of study formal consent is not required. 
